Table 1

Baseline Characteristics of Patients in Both Randomized Groups

Target Group (n = 110)Control Group (n = 110)
Age, yrs72 (65/76)72 (64/80)
Male85 (77)88 (80)
NYHA functional class III/IV95/1593/17
Ischemic cardiomyopathy62 (56)61 (56)
Diabetes mellitus30 (27)29 (26)
Previous CABG35 (32)29 (26)
Previous MI56 (51)58 (53)
QRS duration, ms157 (148/170)159 (146/170)
LVEDV, ml198 (152/231)198 (166/221)
LVESV, ml152 (118/183)149 (130/176)
LVEF, %23 (19/28)24 (18/29)
Moderate/severe mitral regurgitation24 (22)27 (25)
ACEI80 (73)77 (70)
ARB24 (22)26 (24)
ACEI or ARB104 (95)103 (94)
Beta-blockers78 (71)77 (70)
Spironolactone63 (57)59 (54)
Loop diuretics100 (100)100 (100)
LV filling time, ratio0.41 (0.37/0.46)0.40 (0.35/0.46)
IVMD, ms43 (22/61)41 (25/57)
AS-P wall delay, ms187 (101/320)177 (120/336)

Values are median (25th/75th percentile) or n (%).

ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; AS-P = anteroseptal-posterior; CABG = coronary artery bypass grafting; IVMD = interventricular mechanical delay; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; MI = myocardial infarction; NYHA = New York Heart Association.